We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$5.8B
AUM Growth
-$877M
Cap. Flow
-$1.06B
Cap. Flow %
-18.34%
Top 10 Hldgs %
67.63%
Holding
285
New
60
Increased
42
Reduced
77
Closed
80

Top Buys

Rank Stock Value
1
MCD icon
McDonald's
MCD
+$31.9M
2
GEHC icon
GE HealthCare
GEHC
+$31.5M
3
IBRX icon
ImmunityBio
IBRX
+$20.9M
4
GTLB icon
GitLab
GTLB
+$14.8M
5
VSTM icon
Verastem
VSTM
+$13.4M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$52.3M
2
SPB icon
Spectrum Brands
SPB
+$49.4M
3
SMPL icon
Simply Good Foods
SMPL
+$46.6M
4
SAM icon
Boston Beer
SAM
+$42M
5
DPZ icon
Domino's
DPZ
+$41.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 54.52%
2 Healthcare 31.42%
3 Consumer Discretionary 5.85%
4 Technology 4.99%
5 Consumer Staples 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$811B
$1.51B 26.12%
2,450,000
– –
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.3B
$1.51B 26.06%
7,000,000
+300,000
+4% +$60.4M
PTCT icon
3
PTC Therapeutics
PTCT
$5.78B
$231M 3.99%
4,735,464
-699,379
-13% -$33.2M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.49B
$152M 2.62%
4,812,000
-384,000
-7% -$12.3M
TVTX icon
5
Travere Therapeutics
TVTX
$6.25B
$131M 2.27%
8,876,000
+4,000
+0% +$66.3K
INCY icon
6
Incyte
INCY
$25.5B
$91M 1.57%
1,336,000
-335,463
-20% -$21.3M
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.9B
$85M 1.47%
676,024
-324,166
-32% -$37.2M
IMVT icon
8
Immunovant
IMVT
$8.17B
$83.2M 1.44%
5,200,000
+700,000
+16% +$10.6M
GRFS
9
Grifois
GRFS
$5.29B
$66M 1.14%
7,298,000
-1,980,000
-21% -$15.5M
GEHC icon
10
GE HealthCare
GEHC
$30.3B
$56M 0.97%
756,281
+453,221
+150% +$31.5M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$83.8B
$52.5M 0.91%
100,032
-14,041
-12% -$7.84M
MDGL icon
12
CALL
Madrigal Pharmaceuticals
MDGL
$12.4B
$51.4M 0.89%
170,000
-130,000
-43% -$38.7M
FIVN icon
13
FIVE9
FIVN
$2.34B
$48.6M 0.84%
1,836,000
-262,000
-12% -$6.82M
AMZN icon
14
Amazon
AMZN
$2.77T
$48.1M 0.83%
219,423
-44,703
-17% -$8.85M
STAA icon
15
STAAR Surgical
STAA
$1.21B
$47.2M 0.81%
2,812,000
-188,000
-6% -$3.31M
CYTK icon
16
CALL
Cytokinetics
CYTK
$10.5B
$44.3M 0.76%
1,340,000
-1,360,000
-50% -$47.3M
ARGX icon
17
argenx
ARGX
$63.1B
$44.1M 0.76%
80,000
-18,000
-18% -$10.4M
CYTK icon
18
Cytokinetics
CYTK
$10.5B
$43.4M 0.75%
1,312,349
+288,959
+28% +$10.1M
MCD icon
19
McDonald's
MCD
$181B
$41.9M 0.72%
143,580
+103,580
+259% +$31.9M
MSFT icon
20
Microsoft
MSFT
$3.65T
$41.7M 0.72%
83,737
-48,263
-37% -$21M
EXAS
21
DELISTED
Exact Sciences
EXAS
$39.4M 0.68%
741,956
-1,030,413
-58% -$52.3M
AGIO icon
22
Agios Pharmaceuticals
AGIO
$2.01B
$38.8M 0.67%
1,168,000
-880,000
-43% -$26.7M
FRPT icon
23
Freshpet
FRPT
$3.31B
$38.4M 0.66%
565,403
-151,557
-21% -$11.8M
FIVN icon
24
CALL
FIVE9
FIVN
$2.34B
$37.6M 0.65%
+1,420,000
New +$37M
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$12.4B
$37.5M 0.65%
124,000
-11,883
-9% -$3.54M
1
2 3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Armistice Capital held 285 positions worth $5.8B, down 13% from $6.67B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Armistice Capital withdrew a net $1.06B in Q2 2025, closing 80 positions and reducing 77 holdings. Its most notable exit was Spectrum Brands, an estimated $49.4M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 55% of assets, up from 44% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Armistice Capital opened a new position in ImmunityBio worth $20.5M.

  • Armistice Capital's largest Q2 2025 buy was ImmunityBio: 7,764,000 shares worth $20.5M.
  • Armistice Capital added most to McDonald's in Q2 2025, an estimated $31.9M increase.
  • Armistice Capital's biggest Q2 2025 reduction was Exact Sciences, cutting an estimated $52.3M.
  • Armistice Capital fully exited Spectrum Brands in Q2 2025, selling an estimated $49.4M.
  • Armistice Capital's ten largest holdings make up 68% of its $5.8B portfolio in Q2 2025.
  • Armistice Capital opened 60 new positions and closed 80 in Q2 2025.
  • Armistice Capital's portfolio value fell 13% quarter-over-quarter to $5.8B.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.